207 related articles for article (PubMed ID: 23664753)
1. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
[TBL] [Abstract][Full Text] [Related]
2. G2019S LRRK2 mutation causing Parkinson's disease without Lewy bodies.
Gaig C; Martí MJ; Ezquerra M; Rey MJ; Cardozo A; Tolosa E
J Neurol Neurosurg Psychiatry; 2007 Jun; 78(6):626-8. PubMed ID: 17210620
[TBL] [Abstract][Full Text] [Related]
3. Neuropathology of Parkinson's disease associated with the LRRK2 Ile1371Val mutation.
Giordana MT; D'Agostino C; Albani G; Mauro A; Di Fonzo A; Antonini A; Bonifati V
Mov Disord; 2007 Jan; 22(2):275-8. PubMed ID: 17149743
[TBL] [Abstract][Full Text] [Related]
4. Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.
Gaig C; Ezquerra M; Martí MJ; Valldeoriola F; Muñoz E; Lladó A; Rey MJ; Cardozo A; Molinuevo JL; Tolosa E
J Neurol Sci; 2008 Jul; 270(1-2):94-8. PubMed ID: 18353371
[TBL] [Abstract][Full Text] [Related]
5. Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
Agin-Liebes J; Hickman RA; Vonsattel JP; Faust PL; Flowers X; Utkina Sosunova I; Ntiri J; Mayeux R; Surface M; Marder K; Fahn S; Przedborski S; Alcalay RN
Mov Disord; 2023 Aug; 38(8):1541-1545. PubMed ID: 37218402
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
7. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
[TBL] [Abstract][Full Text] [Related]
8. First neuropathological description of a patient with Parkinson's disease and LRRK2 p.N1437H mutation.
Puschmann A; Englund E; Ross OA; Vilariño-Güell C; Lincoln SJ; Kachergus JM; Cobb SA; Törnqvist AL; Rehncrona S; Widner H; Wszolek ZK; Farrer MJ; Nilsson C
Parkinsonism Relat Disord; 2012 May; 18(4):332-8. PubMed ID: 22154298
[TBL] [Abstract][Full Text] [Related]
9. LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
Lubben N; Brynildsen JK; Webb CM; Li HL; Leyns CEG; Changolkar L; Zhang B; Meymand ES; O'Reilly M; Madaj Z; DeWeerd D; Fell MJ; Lee VMY; Bassett DS; Henderson MX
Transl Neurodegener; 2024 Mar; 13(1):13. PubMed ID: 38438877
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
11. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation.
Wider C; Dickson DW; Wszolek ZK
Neurodegener Dis; 2010; 7(1-3):175-9. PubMed ID: 20197701
[TBL] [Abstract][Full Text] [Related]
12. LRRK2 I2020T mutation is associated with tau pathology.
Ujiie S; Hatano T; Kubo S; Imai S; Sato S; Uchihara T; Yagishita S; Hasegawa K; Kowa H; Sakai F; Hattori N
Parkinsonism Relat Disord; 2012 Aug; 18(7):819-23. PubMed ID: 22525366
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
[TBL] [Abstract][Full Text] [Related]
14. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
15. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons.
Henderson MX; Changolkar L; Trojanowski JQ; Lee VMY
J Parkinsons Dis; 2021; 11(3):1187-1196. PubMed ID: 33720852
[TBL] [Abstract][Full Text] [Related]
16. Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.
Devine MJ; Lewis PA
FEBS J; 2008 Dec; 275(23):5748-57. PubMed ID: 19021752
[TBL] [Abstract][Full Text] [Related]
17. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
18. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
[TBL] [Abstract][Full Text] [Related]
19. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2.
Martí-Massó JF; Ruiz-Martínez J; Bolaño MJ; Ruiz I; Gorostidi A; Moreno F; Ferrer I; López de Munain A
Mov Disord; 2009 Oct; 24(13):1998-2001. PubMed ID: 19735093
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and pathological characterization of Lrrk2.
Giasson BI; Covy JP; Bonini NM; Hurtig HI; Farrer MJ; Trojanowski JQ; Van Deerlin VM
Ann Neurol; 2006 Feb; 59(2):315-22. PubMed ID: 16437584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
